Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CORI Corium International (CORI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Corium International Stock (NASDAQ:CORI) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. Get Corium International alerts:Sign Up Key Stats Today's Range$12.68▼$12.6850-Day Range N/A52-Week Range$7.17▼$13.93VolumeN/AAverage Volume577,723 shsMarket Capitalization$459.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCorium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.Read More… The Final Frontier (Ad)And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. Receive CORI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corium International and its competitors with MarketBeat's FREE daily newsletter. Email Address CORI Stock News HeadlinesGlobal Vaccine Delivery Devices Market Analysis & Forecast 2024-2034May 27, 2024 | finance.yahoo.comQUEBEC AI INNOVATION: COGINOV AND CORIUM JOIN FORCES FOR ACCELERATED GROWTHJanuary 22, 2024 | ca.finance.yahoo.comMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicted the 2020 crash a month before it happened...November 5, 2024 | Opportunistic Trader (Ad)Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across AsiaAugust 10, 2023 | businesswire.comBest International Student LoansJuly 6, 2023 | investopedia.comThe 5 Best International Travel Insurance Companies for 2023May 23, 2023 | travel.usnews.comGlobal 2023, Passive Transdermal Drug Delivery Market Analysis of New Report 2030May 15, 2023 | marketwatch.comPassive Transdermal Drug Delivery Market Share by 2031April 28, 2023 | marketwatch.comSee More Headlines CORI Stock Analysis - Frequently Asked Questions How were Corium International's earnings last quarter? Corium International, Inc. (NASDAQ:CORI) posted its quarterly earnings data on Thursday, August, 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.04. The biopharmaceutical company earned $7.67 million during the quarter, compared to analyst estimates of $6.72 million. Corium International had a negative net margin of 155.21% and a negative trailing twelve-month return on equity of 276.89%. What other stocks do shareholders of Corium International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corium International investors own include Bristol-Myers Squibb (BMY), Intelsat (I), Energy Transfer (ET), Iovance Biotherapeutics (IOVA), Exelixis (EXEL), SunCoke Energy Partners (SXCP) and Cypress Semiconductor (CY). Company Calendar Last Earnings8/09/2018Today11/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CORI CUSIPN/A CIK1594337 Webwww.coriumgroup.com Phone650-298-8255FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,790,000.00 Net Margins-155.21% Pretax MarginN/A Return on Equity-276.89% Return on Assets-57.52% Debt Debt-to-Equity Ratio2.83 Current Ratio7.61 Quick Ratio7.47 Sales & Book Value Annual Sales$31.86 million Price / Sales14.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book28.18Miscellaneous Outstanding Shares36,250,000Free FloatN/AMarket Cap$459.65 million OptionableOptionable Beta0.87 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:CORI) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corium International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corium International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.